ClinicalTrials.gg
CompletedNCT02174627Updated Dec 16, 2019Results posted

Safety and Efficacy Study of Roxadustat to Treat Anemia in Patients With Chronic Kidney Disease (CKD), Not on Dialysis

A Phase 3 interventional study of Roxadustat and Placebo in Anemia, sponsored by AstraZeneca. Completed at 360 sites in 26 countries. Open to participants aged 18 Years to 130 Years. Per ClinicalTrials.gov, last updated 2019-12-16.

Sponsored by AstraZeneca · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
2,781
Allocation
Randomized
Ages
18 Years to 130 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 43 studies testing roxadustat in Anemia — 2 open to participants now, 4 under way, 3 of them phase 3. roxadustat · Anemia.

Enrollment
Largest of 43
2,781 · median 154
Started
2014
with 4 others
Phase 3
25 of 43
1 open now
Registered
13th of 43
by date
Lead sponsor
3 of 43
AstraZeneca

Among the 43 studies testing roxadustat in Anemia, this one has the largest enrollment, is one of 5 that started in 2014, is one of 25 in phase 3, and was the 13th registered.

Anemia

1,810 studies on the registry are indexed under Anemia; 215 are open to participants now.

Browse Anemia studies →

Open to participants now

2 of the 43 studies testing roxadustat in Anemia are open now. Recruiting first, the newest first:

All 2 open studies →

About roxadustat

roxadustat: first EMA approval 2021. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 122 Anemia studies recruiting now, 67 (55%) set no upper age limit and 37 (30%) stop at 75 or younger; 34 take children under 18; 23 take healthy volunteers.

This study: 18 Years to 130 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 43 studies testing roxadustat in Anemia, or all of them as a file.
02

Study summary

The purpose of the study is to evaluate the safety and efficacy of roxadustat for treatment of anemia in patients with chronic kidney disease not on dialysis

Read the detailed description

This is a Phase 3, multicenter, randomized, double-blind, placebo-controlled study in anemic patients with Stage 3, 4 or 5 chronic kidney disease (CKD) who are not on dialysis.

03

Conditions studied

  • Anemia

Browse trials for

Keywords

  • Renal,
  • CKD,
  • Roxadustat,
  • anemia,
  • non-dialysis
04

Who can participate

Ages eligible
18 Years to 130 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Provision of prior to any study specific procedures.
  2. Age ≥18 years at screening visit 1
  3. \<60 mL/min/1.73 m2, (calculated by central lab) corresponding to stage 3, 4 or 5CKD according to the Kidney Disease Outcomes Quality Initiative (KDOQI), not receiving dialysis
  4. Mean of 2 most recent central laboratory values during the screening period, obtained at least 7 days apart, must be \<10.0 g/dL
  5. Ferritin ≥50 ng/mL at randomization (obtained from screening visit)
  6. TSAT ≥15 % at randomization (obtained from screening visit)
  7. Serum folate level ≥ lower limit of normal (LLN) at randomization (obtained from screening visit)
  8. Serum vitamin B12 level ≥LLN at randomization (obtained from screening visit)
  9. (ALT) and aspartate aminotransferase (AST) ≤3 x (ULN) and total (Tbili) ≤1.5 x ULN at randomization (obtained from screening visit)
  10. Body weight 45 to 160 kg

Exclusion criteria

Exclusion Criteria:

  1. Involvement in the planning and/or conduct of the study (applies to both AstraZeneca staff and/or staff at the study site)
  2. Previous randomization in the present study
  3. Any erythropoietin analogue treatment within 6 weeks of randomization
  4. Class III or IV congestive heart failure at enrollment
  5. Myocardial infarction (MI), acute coronary syndrome, stroke, seizure or a thrombotic/thromboembolic event (e.g., deep vein thrombosis or pulmonary embolism) within 12 weeks prior to randomization
  6. History of chronic liver disease (e.g., chronic infectious hepatitis, chronic auto- immune liver disease, cirrhosis or fibrosis of the liver)
  7. Known hereditary hematologic disease such as thalassemia, sickle cell anemia, a history of pure red cell aplasia or other known causes for anemia other than CKD
  8. Known and untreated retinal vein occlusion or known and untreated proliferative diabetic retinopathy (risk for retinal vein thrombosis)
  9. Diagnosis or suspicion (e.g. complex kidney cyst of Bosniak Category IIF, III or IV) of renal cell carcinoma on renal ultrasound (or other imaging procedure e.g. CT scan or MRI) conducted at screening or within 12 weeks prior to randomization
  10. Systolic BP ≥160 mmHg or diastolic BP ≥95 mmHg (confirmed by repeated measurement), within 2 weeks prior to randomization. Patients may be rescreened once BP controlled
  11. History of prostate cancer, breast cancer or any other , except the following: cancers determined to be cured or in remission for ≥5 years, curatively resected basal cell or squamous cell skin cancers, cervical cancer in situ, or resected colonic polyps
  12. Positive for any of the following: (HIV), surface antigen (HBsAg) or anti- virus antibody (anti-HCV Ab)
  13. Chronic inflammatory diseases such as rheumatoid arthritis, systemic lupus erythematosus (SLE), ankylosing spondylitis, psoriatic arthritis or inflammatory bowel disease that is determined to be the principal cause of anemia
  14. Known hemosiderosis, hemochromatosis or hypercoagulable condition
  15. Any prior organ transplant or a scheduled organ transplantation date
  16. Any red blood cell transfusion (RBC) during the screening period
  17. Any current condition leading to active significant blood loss
  18. Any treatment with roxadustat or a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI)
  19. Has received another new chemical entity (defined as a compound which has not been approved for marketing) or has participated in any other clinical study that included drug treatment within at least 1 month of the first administration of IP in this study. (Note: patients consented and screened, but not randomized in this study or a previous study are not excluded)
  20. History of alcohol or drug abuse within 2 years prior to randomization
  21. Females of , unless using as detailed in the protocol or sexual abstinence
  22. Pregnant or breastfeeding females
  23. Known allergy to the product or any of its ingredients
  24. Any medical condition, including active, infection, that in the opinion of the investigator or Sponsor may pose a safety risk to a patient in this study, which may confound efficacy or safety assessment or may interfere with study participation
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
2,781 participants (actual)

Study arms

  • Experimental
    Roxadustat

    Drug: Roxadustat

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • The initial study drug dose is 70 mg three times a week (TIW). The dose is subsequently adjusted to achieve and maintain Hb 11±1 g/dL.

  • DrugPlacebo

    The initial study drug dose is 70 mg three times a week (TIW). The dose is subsequently adjusted to achieve and maintain Hb 11±1 g/dL.

06

What researchers measure

Primary outcomes

  1. Mean Change From Baseline in Hb Averaged Over Week 28 to Week 52

    Baseline Hb was defined as the mean of the last 3 central laboratory Hb values from the screening and randomization visits. Mean change in Hb from baseline to mean value from Week 28 to Week 52 was analyzed using a missing at random (MAR) based multiple imputation analysis of covariance (ANCOVA) model with baseline Hb, baseline estimated glomerular filtration rate (eGFR), cardiovascular (CV) history, geographic region and treatment group as fixed effect covariates. The adjusted least squares (LS) mean estimates of change from baseline to mean during Week 28 to Week 52 are presented.

    Time frame: Baseline (Day 1, Week 0) and Week 28 to Week 52.

Secondary outcomes

  1. Percentage of Participants With Hb Response During the First 24 Weeks of Treatment

    Hb response was defined as: * Hb ≥ 11.0 g/dL and Hb increase from baseline by ≥ 1.0 g/dL for participants with baseline Hb \> 8.0 g/dL; or * Hb increase from baseline by ≥ 2.0 g/dL, for participants with baseline Hb ≤ 8.0 g/dL at 2 consecutive visits (with available data) separated at least 5 days during the first 24 weeks of treatment without having received rescue therapy (red blood cell \[RBC\] transfusion, erythropoietin analogue, or intravenous \[IV\] iron) prior to Hb response. The percentage of participants with an Hb response during the first 24 weeks of treatment is presented.

    Time frame: Baseline (Day 1, Week 0) up to Week 24.

  2. Mean Change From Baseline in Hb Averaged Over Week 28 to Week 52 in Participants With Baseline High Sensitivity C-Reactive Protein (hsCRP) Greater Than the Upper Limit of Normal (ULN)

    Baseline hsCRP was quantified from stored biomarker samples obtained at randomization. Baseline Hb was defined as the mean of the last 3 central laboratory Hb values from the screening and randomization visits. Mean change in Hb from baseline to mean value during Week 28 to Week 52 was analyzed using a MAR based multiple imputation ANCOVA model with baseline Hb, baseline eGFR, CV history, geographic region and treatment group as fixed effect covariates. The adjusted LS mean estimates of change from baseline in participants with baseline hsCRP \>ULN to mean during Week 28 to Week 52 are presented.

    Time frame: Baseline (Day 1, Week 0) and Week 28 to Week 52.

  3. Proportion of Total Time of Interpolated Hb Values Greater Than or Equal To 10 g/dL From Week 28 to Week 52

    Proportion of total time of interpolated Hb values ≥10 g/dL was calculated as the time the linearly interpolated curve between measurements ≥10 g/dL divided by the time between measurements from Week 28 to Week 52. Proportion of total time was analyzed using an ANCOVA model with baseline Hb and baseline eGFR as covariates, and CV history, geographic region and treatment group as fixed effects. The adjusted LS mean estimates of change from Week 28 to Week 52 are presented.

    Time frame: Week 28 up to Week 52.

  4. Proportion of Total Time of Interpolated Hb Values Within the Interval of 10 to 12 g/dL From Week 28 to Week 52

    Proportion of total time of interpolated Hb values within the interval of 10 to 12 g/dL was calculated as the time the linearly interpolated curve between measurements were within 10 to 12 g/dL divided by the time between measurements from Week 28 to Week 52. Proportion of total time was analyzed using an ANCOVA model with baseline Hb and baseline eGFR as covariates, and CV history, geographic region and treatment group as fixed effects. The adjusted LS mean estimates of change from Week 28 to Week 52 are presented.

    Time frame: Week 28 up to Week 52.

  5. Mean Change in Low-Density Lipoprotein (LDL) Cholesterol From Baseline to Week 24

    Baseline LDL was defined as the last result obtained prior to randomization. Mean changes in LDL cholesterol from baseline to Week 24 was analyzed using an ANCOVA model with baseline LDL, baseline Hb and baseline eGFR as covariates, and CV history, geographic region and treatment group as fixed effects. The adjusted LS mean estimates of change from baseline to Week 24 are presented.

    Time frame: Baseline (Day 1, Week 0) and Week 24

  6. Time-To-First Instance of Receiving IV Iron, RBC Transfusion or Erythropoietin Analogue as Rescue Therapy

    Time-to-first rescue therapy (IV iron, RBC transfusion or erythropoietin analogue) was calculated as (date of first rescue therapy, or date of censoring if no rescue therapy was taken) minus (date of first dose of IP) +1. Event rate was calculated as (number of participants with event) divided by (the total number of days at risk for event across all participants in given group divided by 365.25) multiplied by 100. The event rate is presented for participants with events.

    Time frame: Baseline (Day1, Week 0) up to End of Study (EOS) visit (4 weeks after the treatment period) (or up to date of first rescue therapy), with treatment duration up to 4 years.

  7. Time-To-First Instance of Receiving a RBC Transfusion As Rescue Therapy

    Time-to-first RBC rescue therapy was calculated as (date of first RBC rescue therapy, or date of censoring if no rescue therapy was taken) minus (date of first dose of IP) +1. Event rate was calculated as (number of participants with event) divided by (the total number of days at risk for event across all participants in given group divided by 365.25) multiplied by 100. The event rate is presented for participants with events.

    Time frame: Baseline (Day1, Week 0) up to EOS visit (4 weeks after the treatment period) (or up to date of first RBC rescue therapy), with treatment duration up to 4 years.

  8. Mean Change From Baseline in Short Form 36 (SF-36) Vitality Sub-Score From Week 12 to Week 28

    SF-36 is a Quality of Life (QoL) scale comprising 8 domains of health status: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role Emotional and Mental Health. Each domain score is on a scale from 0-100 (worst health possible to best health possible); higher scores indicate better health status. Mean change in SF-36 Vitality sub-score from baseline to mean from Week 12 to Week 28 was analyzed using a mixed model for repeated measures (MMRM) with terms for baseline score, treatment group, baseline Hb, baseline eGFR, CV history, geographic region, visit and treatment-by-visit interaction as fixed effects and participant as random effect. The adjusted LS mean estimates of change from baseline to mean score from Week 12 to Week 28 are presented.

    Time frame: Baseline (Day 1, Week 0) and Week 12 to Week 28.

  9. Annual Rate of eGFR Change From Baseline Prior to the Initiation of Dialysis or Kidney Transplant

    Baseline eGFR was defined as the mean of all available central laboratory values prior to or at randomization. Rate of change in eGFR from baseline during the entire treatment period (in millilitres/minute/1.73 meters squared/years \[mL/min/1.73m\^2/years\]) was estimated using a random effects model using all post-baseline eGFR values prior to initiation of dialysis/transplant. Baseline eGFR, baseline Hb, geographic region, CV history, treatment group and post-baseline eGFR measurement time were used as fixed effects and participant and time (years) as random effects, ie, random intercept and slope.

    Time frame: Baseline (Day1, Week 0) up to EOS visit (4 weeks after the treatment period), with treatment duration up to 4 years.

  10. Mean Change From Baseline in SF-36 Physical Functioning Sub-Score From Week 12 to Week 28

    SF-36 is a QoL scale comprising 8 domains of health status: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role Emotional and Mental Health. Each domain score is on a scale from 0-100 (worst health possible to best health possible); higher scores indicate better health status. Mean change in SF-36 Physical Functioning sub-score from baseline to mean from Week 12 to Week 28 was analyzed using a MMRM with terms for baseline score, treatment group, baseline Hb, baseline eGFR, CV history, geographic region, visit and treatment-by-visit interaction as fixed effects and participant as random effect. The adjusted LS mean estimates of change from baseline to mean score from Week 12 to Week 28 are presented.

    Time frame: Baseline (Day 1, Week 0) and Week 12 to Week 28.

07

Results

Posted Dec 16, 2019
Limitations and caveats
20 participants were excluded from the analysis due to Good Clinical Practice violations or system technical issues (9 in roxadustat group and 11 in placebo group). Higher IP discontinuation was observed in placebo group versus in roxadustat group.

Participant flow

This study was conducted at 385 centers in 25 countries worldwide across the United States, Canada, Latin America, Asia and Europe between 26 June 2014 and 04 October 2018. Participants with chronic kidney disease who were not on dialysis were recruited in this study.

Participant flow — Overall Study
MilestoneRoxadustatPlacebo
Started13841377
Received treatment13841376
Discontinued treatment499801
Completed13001247
Not completed84130
Withdrew: Missing01
Withdrew: Incorrect enrolment before randomization01
Withdrew: Participant decision84128

Outcome measures

PrimaryMean Change From Baseline in Hb Averaged Over Week 28 to Week 52

Baseline Hb was defined as the mean of the last 3 central laboratory Hb values from the screening and randomization visits. Mean change in Hb from baseline to mean value from Week 28 to Week 52 was analyzed using a missing at random (MAR) based multiple imputation analysis of covariance (ANCOVA) model with baseline Hb, baseline estimated glomerular filtration rate (eGFR), cardiovascular (CV) history, geographic region and treatment group as fixed effect covariates. The adjusted least squares (LS) mean estimates of change from baseline to mean during Week 28 to Week 52 are presented.

Time frame:
Baseline (Day 1, Week 0) and Week 28 to Week 52.
Reported as:
Least squares mean · g/dL
Mean Change From Baseline in Hb Averaged Over Week 28 to Week 52
g/dLRoxadustatPlacebo
Mean Change From Baseline in Hb Averaged Over Week 28 to Week 521.75 ± 0.0330.40 ± 0.034
Statistical analysis
  • Roxadustat vs Placebo · ANCOVA · p = <0.001 · Ls mean difference: 1.35 · 95% CI 1.27 to 1.43
SecondaryPercentage of Participants With Hb Response During the First 24 Weeks of Treatment

Hb response was defined as: * Hb ≥ 11.0 g/dL and Hb increase from baseline by ≥ 1.0 g/dL for participants with baseline Hb \> 8.0 g/dL; or * Hb increase from baseline by ≥ 2.0 g/dL, for participants with baseline Hb ≤ 8.0 g/dL at 2 consecutive visits (with available data) separated at least 5 days during the first 24 weeks of treatment without having received rescue therapy (red blood cell \[RBC\] transfusion, erythropoietin analogue, or intravenous \[IV\] iron) prior to Hb response. The percentage of participants with an Hb response during the first 24 weeks of treatment is presented.

Time frame:
Baseline (Day 1, Week 0) up to Week 24.
Reported as:
Number · Percentage of participants
Percentage of Participants With Hb Response During the First 24 Weeks of Treatment
Percentage of participantsRoxadustatPlacebo
Percentage of Participants With Hb Response During the First 24 Weeks of Treatment77.08.5
Statistical analysis
  • Roxadustat vs Placebo · Cochran-Mantel-Haenszel · p = <0.001 · Relative risk: 9.12 · 95% CI 7.63 to 10.89
SecondaryMean Change From Baseline in Hb Averaged Over Week 28 to Week 52 in Participants With Baseline High Sensitivity C-Reactive Protein (hsCRP) Greater Than the Upper Limit of Normal (ULN)

Baseline hsCRP was quantified from stored biomarker samples obtained at randomization. Baseline Hb was defined as the mean of the last 3 central laboratory Hb values from the screening and randomization visits. Mean change in Hb from baseline to mean value during Week 28 to Week 52 was analyzed using a MAR based multiple imputation ANCOVA model with baseline Hb, baseline eGFR, CV history, geographic region and treatment group as fixed effect covariates. The adjusted LS mean estimates of change from baseline in participants with baseline hsCRP \>ULN to mean during Week 28 to Week 52 are presented.

Time frame:
Baseline (Day 1, Week 0) and Week 28 to Week 52.
Reported as:
Least squares mean · g/dL
Mean Change From Baseline in Hb Averaged Over Week 28 to Week 52 in Participants With Baseline High Sensitivity C-Reactive Protein (hsCRP) Greater Than the Upper Limit of Normal (ULN)
g/dLRoxadustatPlacebo
Mean Change From Baseline in Hb Averaged Over Week 28 to Week 52 in Participants With Baseline High Sensitivity C-Reactive Protein (hsCRP) Greater Than the Upper Limit of Normal (ULN)1.75 ± 0.0870.62 ± 0.091
Statistical analysis
  • Roxadustat vs Placebo · ANCOVA · p = <0.001 · Ls mean difference: 1.13 · 95% CI 0.91 to 1.35
SecondaryProportion of Total Time of Interpolated Hb Values Greater Than or Equal To 10 g/dL From Week 28 to Week 52

Proportion of total time of interpolated Hb values ≥10 g/dL was calculated as the time the linearly interpolated curve between measurements ≥10 g/dL divided by the time between measurements from Week 28 to Week 52. Proportion of total time was analyzed using an ANCOVA model with baseline Hb and baseline eGFR as covariates, and CV history, geographic region and treatment group as fixed effects. The adjusted LS mean estimates of change from Week 28 to Week 52 are presented.

Time frame:
Week 28 up to Week 52.
Reported as:
Least squares mean · proportion of total time
Proportion of Total Time of Interpolated Hb Values Greater Than or Equal To 10 g/dL From Week 28 to Week 52
proportion of total timeRoxadustatPlacebo
Proportion of Total Time of Interpolated Hb Values Greater Than or Equal To 10 g/dL From Week 28 to Week 520.82 ± 0.0110.33 ± 0.011
Statistical analysis
  • Roxadustat vs Placebo · ANCOVA · p = <0.001 · Ls mean difference: 0.50 · 95% CI 0.47 to 0.52
SecondaryProportion of Total Time of Interpolated Hb Values Within the Interval of 10 to 12 g/dL From Week 28 to Week 52

Proportion of total time of interpolated Hb values within the interval of 10 to 12 g/dL was calculated as the time the linearly interpolated curve between measurements were within 10 to 12 g/dL divided by the time between measurements from Week 28 to Week 52. Proportion of total time was analyzed using an ANCOVA model with baseline Hb and baseline eGFR as covariates, and CV history, geographic region and treatment group as fixed effects. The adjusted LS mean estimates of change from Week 28 to Week 52 are presented.

Time frame:
Week 28 up to Week 52.
Reported as:
Least squares mean · proportion of total time
Proportion of Total Time of Interpolated Hb Values Within the Interval of 10 to 12 g/dL From Week 28 to Week 52
proportion of total timeRoxadustatPlacebo
Proportion of Total Time of Interpolated Hb Values Within the Interval of 10 to 12 g/dL From Week 28 to Week 520.70 ± 0.0100.28 ± 0.010
Statistical analysis
  • Roxadustat vs Placebo · ANCOVA · p = <0.001 · Ls mean difference: 0.42 · 95% CI 0.40 to 0.45
SecondaryMean Change in Low-Density Lipoprotein (LDL) Cholesterol From Baseline to Week 24

Baseline LDL was defined as the last result obtained prior to randomization. Mean changes in LDL cholesterol from baseline to Week 24 was analyzed using an ANCOVA model with baseline LDL, baseline Hb and baseline eGFR as covariates, and CV history, geographic region and treatment group as fixed effects. The adjusted LS mean estimates of change from baseline to Week 24 are presented.

Time frame:
Baseline (Day 1, Week 0) and Week 24
Reported as:
Least squares mean · millimole per liter
Mean Change in Low-Density Lipoprotein (LDL) Cholesterol From Baseline to Week 24
millimole per literRoxadustatPlacebo
Mean Change in Low-Density Lipoprotein (LDL) Cholesterol From Baseline to Week 24-0.38 ± 0.028-0.02 ± 0.027
Statistical analysis
  • Roxadustat vs Placebo · ANCOVA · p = <0.001 · Ls mean difference: -0.36 · 95% CI -0.42 to -0.29
SecondaryTime-To-First Instance of Receiving IV Iron, RBC Transfusion or Erythropoietin Analogue as Rescue Therapy

Time-to-first rescue therapy (IV iron, RBC transfusion or erythropoietin analogue) was calculated as (date of first rescue therapy, or date of censoring if no rescue therapy was taken) minus (date of first dose of IP) +1. Event rate was calculated as (number of participants with event) divided by (the total number of days at risk for event across all participants in given group divided by 365.25) multiplied by 100. The event rate is presented for participants with events.

Time frame:
Baseline (Day1, Week 0) up to End of Study (EOS) visit (4 weeks after the treatment period) (or up to date of first rescue therapy), with treatment duration up to 4 years.
Reported as:
Number · Events per 100 participant years
Time-To-First Instance of Receiving IV Iron, RBC Transfusion or Erythropoietin Analogue as Rescue Therapy
Events per 100 participant yearsRoxadustatPlacebo
Time-To-First Instance of Receiving IV Iron, RBC Transfusion or Erythropoietin Analogue as Rescue Therapy11.9039.76
Statistical analysis
  • Roxadustat vs Placebo · Regression, Cox · p = <0.001 · Hazard ratio (hr): 0.26 · 95% CI 0.23 to 0.31
SecondaryTime-To-First Instance of Receiving a RBC Transfusion As Rescue Therapy

Time-to-first RBC rescue therapy was calculated as (date of first RBC rescue therapy, or date of censoring if no rescue therapy was taken) minus (date of first dose of IP) +1. Event rate was calculated as (number of participants with event) divided by (the total number of days at risk for event across all participants in given group divided by 365.25) multiplied by 100. The event rate is presented for participants with events.

Time frame:
Baseline (Day1, Week 0) up to EOS visit (4 weeks after the treatment period) (or up to date of first RBC rescue therapy), with treatment duration up to 4 years.
Reported as:
Number · Events per 100 participant years
Time-To-First Instance of Receiving a RBC Transfusion As Rescue Therapy
Events per 100 participant yearsRoxadustatPlacebo
Time-To-First Instance of Receiving a RBC Transfusion As Rescue Therapy7.9819.61
Statistical analysis
  • Roxadustat vs Placebo · Regression, Cox · p = <0.001 · Hazard ratio (hr): 0.37 · 95% CI 0.30 to 0.44
SecondaryMean Change From Baseline in Short Form 36 (SF-36) Vitality Sub-Score From Week 12 to Week 28

SF-36 is a Quality of Life (QoL) scale comprising 8 domains of health status: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role Emotional and Mental Health. Each domain score is on a scale from 0-100 (worst health possible to best health possible); higher scores indicate better health status. Mean change in SF-36 Vitality sub-score from baseline to mean from Week 12 to Week 28 was analyzed using a mixed model for repeated measures (MMRM) with terms for baseline score, treatment group, baseline Hb, baseline eGFR, CV history, geographic region, visit and treatment-by-visit interaction as fixed effects and participant as random effect. The adjusted LS mean estimates of change from baseline to mean score from Week 12 to Week 28 are presented.

Time frame:
Baseline (Day 1, Week 0) and Week 12 to Week 28.
Reported as:
Least squares mean · scores on a scale
Mean Change From Baseline in Short Form 36 (SF-36) Vitality Sub-Score From Week 12 to Week 28
scores on a scaleRoxadustatPlacebo
Mean Change From Baseline in Short Form 36 (SF-36) Vitality Sub-Score From Week 12 to Week 281.59 ± 0.2311.15 ± 0.233
Statistical analysis
  • Roxadustat vs Placebo · Mixed Models Analysis · p = 0.120 · Ls mean difference: 0.44 · 95% CI -0.11 to 0.99
SecondaryAnnual Rate of eGFR Change From Baseline Prior to the Initiation of Dialysis or Kidney Transplant

Baseline eGFR was defined as the mean of all available central laboratory values prior to or at randomization. Rate of change in eGFR from baseline during the entire treatment period (in millilitres/minute/1.73 meters squared/years \[mL/min/1.73m\^2/years\]) was estimated using a random effects model using all post-baseline eGFR values prior to initiation of dialysis/transplant. Baseline eGFR, baseline Hb, geographic region, CV history, treatment group and post-baseline eGFR measurement time were used as fixed effects and participant and time (years) as random effects, ie, random intercept and slope.

Time frame:
Baseline (Day1, Week 0) up to EOS visit (4 weeks after the treatment period), with treatment duration up to 4 years.
Reported as:
Number · eGFR rate (mL/min/1.73m^2/years)
Annual Rate of eGFR Change From Baseline Prior to the Initiation of Dialysis or Kidney Transplant
eGFR rate (mL/min/1.73m^2/years)RoxadustatPlacebo
Annual Rate of eGFR Change From Baseline Prior to the Initiation of Dialysis or Kidney Transplant-3.70-3.19
Statistical analysis
  • Roxadustat vs Placebo · Random Effects Analysis · p = 0.046 (Nominal p-value (as prior sequential outcome measure p-value did not meet \< 0.05.) · Rate of change difference: -0.51 · 95% CI -1.00 to -0.01
SecondaryMean Change From Baseline in SF-36 Physical Functioning Sub-Score From Week 12 to Week 28

SF-36 is a QoL scale comprising 8 domains of health status: Physical Functioning, Role-Physical, Bodily Pain, General Health, Vitality, Social Functioning, Role Emotional and Mental Health. Each domain score is on a scale from 0-100 (worst health possible to best health possible); higher scores indicate better health status. Mean change in SF-36 Physical Functioning sub-score from baseline to mean from Week 12 to Week 28 was analyzed using a MMRM with terms for baseline score, treatment group, baseline Hb, baseline eGFR, CV history, geographic region, visit and treatment-by-visit interaction as fixed effects and participant as random effect. The adjusted LS mean estimates of change from baseline to mean score from Week 12 to Week 28 are presented.

Time frame:
Baseline (Day 1, Week 0) and Week 12 to Week 28.
Reported as:
Least squares mean · scores on a scale
Mean Change From Baseline in SF-36 Physical Functioning Sub-Score From Week 12 to Week 28
scores on a scaleRoxadustatPlacebo
Mean Change From Baseline in SF-36 Physical Functioning Sub-Score From Week 12 to Week 280.14 ± 0.222-0.39 ± 0.224
Statistical analysis
  • Roxadustat vs Placebo · Mixed Models Analysis · p = 0.051 (Nominal p-value (as prior sequential outcome measure p-value did not meet \< 0.05.) · Ls mean difference: 0.52 · 95% CI 0.00 to 1.05

Adverse events

Collected over From date of randomization up to EOS visit (4 weeks after the treatment period), with treatment duration up to 4 years.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Roxadustat284/1,384 (20.5%)795/1,384 (57.4%)839/1,384 (60.6%)
Placebo245/1,377 (17.8%)749/1,377 (54.4%)757/1,377 (55%)
Most frequent serious events
Showing 10 of 755
Most frequent serious events
EventRoxadustatPlacebo
End stage renal diseaseRenal and urinary disorders199/1384201/1377
PneumoniaInfections and infestations113/138488/1377
AzotaemiaRenal and urinary disorders61/138460/1377
SepsisInfections and infestations49/138423/1377
DeathGeneral disorders43/138428/1377
HyperkalaemiaMetabolism and nutrition disorders41/138425/1377
Acute kidney injuryRenal and urinary disorders41/138432/1377
Urinary tract infectionInfections and infestations36/138426/1377
Cardiac failure congestiveCardiac disorders33/138431/1377
Hypertensive crisisVascular disorders33/138427/1377
Most frequent other events
Showing 10 of 19
Most frequent other events
EventRoxadustatPlacebo
Urinary tract infectionInfections and infestations152/138494/1377
HypertensionVascular disorders148/1384117/1377
Oedema peripheralGeneral disorders144/1384106/1377
DiarrhoeaGastrointestinal disorders138/1384117/1377
NauseaGastrointestinal disorders124/1384103/1377
Viral upper respiratory tract infectionInfections and infestations101/1384106/1377
CoughRespiratory, thoracic and mediastinal disorders105/138469/1377
Upper respiratory tract infectionInfections and infestations95/138475/1377
HeadacheNervous system disorders93/138482/1377
End stage renal diseaseRenal and urinary disorders93/138487/1377

Baseline characteristics

The Intention-To-Treat (ITT) analysis set included all participants who were randomized to investigational product (IP) irrespective of their protocol adherence and continued participation in the study, except for those excluded from analysis.

Age, Continuous
Age, Continuous(years)RoxadustatPlaceboTotal
Mean60.9 ± 14.6762.4 ± 14.1461.7 ± 14.43
Sex: Female, Male
Sex: Female, Male(Participants)RoxadustatPlaceboTotal
Female8207741594
Male5646031167
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)RoxadustatPlaceboTotal
Hispanic or Latino344357701
Not Hispanic or Latino104010202060
Unknown or Not Reported000
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)RoxadustatPlaceboTotal
White6236111234
Black or African American112115227
Asian5445381082
Native Hawaiian or other Pacific Islander022
American Indian or Alaska Native242953
Other8182163
08

Study locations

360 sites
  • Research Site
    Birmingham, Alabama 35209, United States
  • Research Site
    Huntsville, Alabama 35805, United States
  • Research Site
    Phoenix, Arizona 85027, United States
  • Research Site
    Bakersfield, California 93309, United States
  • Research Site
    El Centro, California 92243, United States
  • Research Site
    Escondido, California 92025, United States
  • Research Site
    Glendale, California 91204, United States
  • Research Site
    Long Beach, California 90806, United States
  • Research Site
    Long Beach, California 90807, United States
  • Research Site
    Los Angeles, California 90022, United States
  • Research Site
    Los Angeles, California 90095, United States
  • Research Site
    Lynwood, California 90262, United States
  • Research Site
    National City, California 91950, United States
  • Research Site
    Northridge, California 91324, United States
  • Research Site
    Orange, California 92868, United States
  • Research Site
    Sacramento, California 95825, United States
  • Research Site
    Sacramento, California 95831, United States
  • Research Site
    San Diego, California 92103, United States
  • Research Site
    San Dimas, California 91773, United States
  • Research Site
    San Francisco, California 94110, United States
  • Research Site
    San Luis Obispo, California 93401, United States
  • Research Site
    Upland, California 91786, United States
  • Research Site
    Arvada, Colorado 80002, United States
  • Research Site
    Waterbury, Connecticut 06708, United States
  • Research Site
    Aventura, Florida 33180, United States
  • Research Site
    Coral Gables, Florida 33134, United States
  • Research Site
    Coral Springs, Florida 33071, United States
  • Research Site
    Edgewater, Florida 32132, United States
  • Research Site
    Hollywood, Florida 33021, United States
  • Research Site
    Kissimmee, Florida 34741, United States
  • Research Site
    Lauderdale Lakes, Florida 33313, United States
  • Research Site
    Miami, Florida 33126, United States
  • Research Site
    Miami, Florida 33130, United States
  • Research Site
    Miami, Florida 33133, United States
  • Research Site
    Miami, Florida 33145, United States
  • Research Site
    Miami, Florida 33150, United States
  • Research Site
    Miami, Florida 33165, United States
  • Research Site
    Miami, Florida 33169, United States
  • Research Site
    Miami, Florida 33173, United States
  • Research Site
    Port Charlotte, Florida 33952, United States
  • Research Site
    Tampa, Florida 33607, United States
  • Research Site
    Atlanta, Georgia 30342, United States
  • Research Site
    Columbus, Georgia 31901, United States
  • Research Site
    Columbus, Georgia 31904, United States
  • Research Site
    Joliet, Illinois 60435, United States
  • Research Site
    La Grange, Illinois 60525, United States
  • Research Site
    Metairie, Louisiana 70006, United States
  • Research Site
    Shreveport, Louisiana 71101, United States
  • Research Site
    Rockport, Maine 04856, United States
  • Research Site
    Greenbelt, Maryland 20770, United States
  • Research Site
    Rockville, Maryland 20852, United States
  • Research Site
    Port Huron, Michigan 48060, United States
  • Research Site
    Gulfport, Mississippi 39501, United States
  • Research Site
    Kansas City, Missouri 64111, United States
  • Research Site
    Omaha, Nebraska 68124, United States
  • Research Site
    Las Vegas, Nevada 89106, United States
  • Research Site
    Las Vegas, Nevada 89128, United States
  • Research Site
    Reno, Nevada 89511, United States
  • Research Site
    Rochester, New Hampshire 03867, United States
  • Research Site
    Flushing, New York 11355, United States
  • Research Site
    Great Neck, New York 11021, United States
  • Research Site
    Charlotte, North Carolina 28207, United States
  • Research Site
    High Point, North Carolina 27262, United States
  • Research Site
    Jacksonville, North Carolina 28546, United States
  • Research Site
    New Bern, North Carolina 28562, United States
  • Research Site
    Wilmington, North Carolina 28401, United States
  • Research Site
    Cincinnati, Ohio 45206, United States
  • Research Site
    Cincinnati, Ohio 45220, United States
  • Research Site
    Columbus, Ohio 43215, United States
  • Research Site
    Oklahoma City, Oklahoma 73116, United States
  • Research Site
    Bethlehem, Pennsylvania 18017, United States
  • Research Site
    Lansdale, Pennsylvania 19446, United States
  • Research Site
    Philadelphia, Pennsylvania 19104, United States
  • Research Site
    Uniontown, Pennsylvania 15401, United States
  • Research Site
    Providence, Rhode Island 02908, United States
  • Research Site
    Providence, Rhode Island 02915, United States
  • Research Site
    Columbia, South Carolina 29203, United States
  • Research Site
    Knoxville, Tennessee 37923, United States
  • Research Site
    Corpus Christi, Texas 78404, United States
  • Research Site
    Cypress, Texas 77429, United States
  • Research Site
    Dallas, Texas 75231, United States
  • Research Site
    Houston, Texas 77004, United States
  • Research Site
    Houston, Texas 77024, United States
  • Research Site
    Houston, Texas 77074, United States
  • Research Site
    Houston, Texas 77084, United States
  • Research Site
    Houston, Texas 77090, United States
  • Research Site
    Houston, Texas 77099, United States
  • Research Site
    Lufkin, Texas 75904, United States
  • Research Site
    San Antonio, Texas 78207, United States
  • Research Site
    San Antonio, Texas 78212, United States
  • Research Site
    San Antonio, Texas 78229, United States
  • Research Site
    San Antonio, Texas 78258, United States
  • Research Site
    Saint George, Utah 84790, United States
  • Research Site
    Salt Lake City, Utah 84115, United States
  • Research Site
    Norfolk, Virginia 23507, United States
  • Research Site
    Salem, Virginia 24153, United States
  • Research Site
    Woodbridge, Virginia 22191, United States
  • Research Site
    Caba, C1012AAR, Argentina
  • Research Site
    Caba, C1440AAD, Argentina
  • Research Site
    Capital Federal, C1425AGC, Argentina

Showing the first 100 of 360 sites across 26 countries. Choose a country and city above to see the rest.

09

References and documents

Publications

  • Natale P, Palmer SC, Jaure A, Hodson EM, Ruospo M, Cooper TE, Hahn D, Saglimbene VM, Craig JC, Strippoli GF. Hypoxia-inducible factor stabilisers for the anaemia of chronic kidney disease. Cochrane Database Syst Rev. 2022 Aug 25;8(8):CD013751. doi: 10.1002/14651858.CD013751.pub2. PubMed 36005278 ↗
  • Provenzano R, Szczech L, Leong R, Saikali KG, Zhong M, Lee TT, Little DJ, Houser MT, Frison L, Houghton J, Neff TB. Efficacy and Cardiovascular Safety of Roxadustat for Treatment of Anemia in Patients with Non-Dialysis-Dependent CKD: Pooled Results of Three Randomized Clinical Trials. Clin J Am Soc Nephrol. 2021 Aug;16(8):1190-1200. doi: 10.2215/CJN.16191020. PubMed 34362786 ↗
  • Fishbane S, El-Shahawy MA, Pecoits-Filho R, Van BP, Houser MT, Frison L, Little DJ, Guzman NJ, Pergola PE. Roxadustat for Treating Anemia in Patients with CKD Not on Dialysis: Results from a Randomized Phase 3 Study. J Am Soc Nephrol. 2021 Mar;32(3):737-755. doi: 10.1681/ASN.2020081150. Epub 2021 Feb 10. PubMed 33568383 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2014 to primary completion in Oct 2018, 51 months.

Results were first posted in Dec 2019, 1 year 2 months after primary completion.

Of 98 industry-sponsored phase 3 interventional studies under Anemia, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 15 and three quarters within 49. This study's 51 months is above that.

Counting every sponsor, half of 149 studies reached it within 30 months; a quarter within 17 and three quarters within 51.

How these figures are worked out, and which studies are left out of them.

Registered
Jun 24, 2014
First posted
Jun 25, 2014
StartActual
Jun 26, 2014
Primary completionActual
Oct 4, 2018
CompletionActual
Oct 4, 2018
Results first posted
Dec 16, 2019
Last update
Dec 16, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 16, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02174627
Lead sponsor
AstraZeneca
Collaborators
FibroGen
Responsible party
Sponsor
First posted
Jun 25, 2014
Start date
Jun 26, 2014
Primary completion
Oct 4, 2018
Completion
Oct 4, 2018
Results posted
Dec 16, 2019
Last update
Dec 16, 2019

Study contacts

Steven Fishbane, MD
principal investigator · Chief Division of Kidney Diseases and Hypertension, North Shore University Hospital, Great Neck, NY, USA
Mark Houser, MD
study director · AZ R&D Gaithersburg, USA

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Roxadustat

Start the discussion